Kyverna Therapeutics, Inc. KYTX 深 滬
已收盤 02-06 16:00:00 美东时间
7.93
+0.660
+9.08%
華盛通- 最 高8.08
- 今 開7.50
- 成交量 78.30万股
- 最 低 7.42
- 昨 收 7.27
- 總市值 4.53亿
- 52周最高 13.67
- 市盈率 靜 --
- 換手率 1.37%
- 52周最低 1.78
- 委 比 -38.79%
- 總股本 5712.95万
- 歷史最高 35.06
- 量 比 0.86
- 振 幅 9.08%
- 歷史最低 1.78
- 每 手 1
- 風險率 2.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Kyverna Therapeutics首席执行官Warner Biddle将于1月14日在旧金山的J.P. Morgan 2026医疗保健会议上发表演讲。公司专注于通过细胞疗法治疗自身免疫疾病，其主要候选药物miv-cel在多個B细胞驱动的自身免疫疾病中顯示潛力。Kyverna正在推进神经免疫学领域的首创疗法，并利用多种試驗評估下一步優先標的。投资者可通过ir.kyvernatx.com观看实时网络直播或查看回放。公司网站kyvernatx.com提供更多信息。
01-05 13:00
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.
2025-12-31 23:01
Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around...
2025-12-26 21:03
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
2025-12-18 01:06
Kyverna Therapeutics Announces ~$100M Public Offering Of ~13.334M Shares At A Price Of $7.50/Share
- Kyverna Therapeutics, Inc. (NASDAQ:KYTX) ("Kyverna"), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the pricing of an
2025-12-17 22:27
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Biggest stock movers Tuesday: RILY, ORGO, KYTX, RC, LWLG and more
U.S. stock futures retreated Tuesday as investors adopted a cautious stance ahead of November’s employment data, a key indicator for the labor market’s health. Here are some of Tuesday's biggest stock...
2025-12-16 18:17
美股牛股 | KYTX大涨超23%，Miv-cel临床试验取得积极成果；以星航运涨近9%，获瑞士航运集团收购要约
KYTX大涨超23%，Miv-cel临床试验取得积极成果；IMNM涨近16%，实验性药物晚期临床试验达主要终点；以星航运涨近9%，获瑞士航运集团收购要约>>
2025-12-16 19:53
Kyverna Therapeutics announces $100M proposed public offering
Kyverna Therapeutics (NASDAQ:KYTX) announced on Monday that it has commenced an underwritten public offering of $100M of shares, and underwriters will be granted a 30-day option to purchase up to an a...
2025-12-16 05:40
Market-Moving News for December 15th
RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Phase 2b Imaging Trial Of RAD 101 In Brain Metastases Showed That 92% Of The Patients Achieved Concordance With
2025-12-15 20:26
